Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Darbepoetin Alfa Administered Three Times Per Week for the Treatment of Anemia in Subjects With Non-myeloid Malignancies Receiving Multicycle Chemotherapy

NCT00239239 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00239239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00239239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Darbepoetin Alfa Administered Three Times Per Week for the Treatment of Anemia in Subjects With Non-myeloid Malignancies Receiving Multicycle Chemotherapy
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2005
Completion date
March 31, 2007
Enrollment
44 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, cancer, non-myeloid malignancies